<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In humans with <z:hpo ids='HP_0001513'>obesity</z:hpo> or type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, insulin target tissues are resistant to many actions of insulin </plain></SENT>
<SENT sid="1" pm="."><plain>The atypical protein kinase C (PKC) isoforms lambda and zeta are downstream of phosphatidylinositol-3 kinase (PI3K) and are required for maximal insulin stimulation of <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="16749">Phosphoinositide</z:chebi>-dependent protein kinase-1 (PDK-1), also downstream of PI3K, mediates activation of atypical PKC isoforms and Akt </plain></SENT>
<SENT sid="3" pm="."><plain>To determine whether impaired PKClambda/zeta or PDK-1 activation plays a role in the pathogenesis of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, we measured the activities of PKClambda/zeta and PDK-1 in vastus lateralis muscle of lean, <z:mp ids='MP_0001261'>obese</z:mp>, and <z:mp ids='MP_0001261'>obese</z:mp>/type 2 diabetic humans </plain></SENT>
<SENT sid="4" pm="."><plain>Biopsies were taken after an overnight fast and after a 3-h hyperinsulinemic-euglycemic clamp </plain></SENT>
<SENT sid="5" pm="."><plain><z:mp ids='MP_0001261'>Obese</z:mp> subjects were also studied after <z:hpo ids='HP_0001824'>weight loss</z:hpo> on a very-low-calorie diet </plain></SENT>
<SENT sid="6" pm="."><plain>Insulin-stimulated <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal rate is reduced 26% in <z:mp ids='MP_0001261'>obese</z:mp> subjects and 62% in diabetic subjects (both comparisons P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Insulin-stimulated insulin receptor substrate (IRS)-1 tyrosine phosphorylation and PI3K activity are impaired 40-50% in diabetic subjects compared with lean or <z:mp ids='MP_0001261'>obese</z:mp> subjects </plain></SENT>
<SENT sid="8" pm="."><plain>Insulin stimulates PKClambda/zeta activity approximately 2.3-fold in lean subjects; the increment above basal is reduced 57% in <z:mp ids='MP_0001261'>obese</z:mp> and 65% in diabetic subjects </plain></SENT>
<SENT sid="9" pm="."><plain>PKClambda/zeta protein amount is decreased 46% in diabetic subjects but is <z:mpath ids='MPATH_458'>normal</z:mpath> in <z:mp ids='MP_0001261'>obese</z:mp> nondiabetic subjects, indicating impaired insulin action on PKClambda/zeta </plain></SENT>
<SENT sid="10" pm="."><plain>Importantly, <z:hpo ids='HP_0001824'>weight loss</z:hpo> in <z:mp ids='MP_0001261'>obese</z:mp> subjects normalizes PKClambda/zeta activation and increases IRS-1 phosphorylation and PI3K activity </plain></SENT>
<SENT sid="11" pm="."><plain>Insulin also stimulates PDK-1 activity approximately twofold with no impairment in <z:mp ids='MP_0001261'>obese</z:mp> or diabetic subjects </plain></SENT>
<SENT sid="12" pm="."><plain>In contrast to our previous data on Akt, reduced insulin-stimulated PKClambda/zeta activity could play a role in the pathogenesis of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in muscle of <z:mp ids='MP_0001261'>obese</z:mp> and type 2 diabetic subjects </plain></SENT>
</text></document>